International Journal of Hematology and Oncology 2020, Vol 30, Num 1 Page(s): 009-014
HEMATOPOIETIC GROWTH FACTOR (G-CSF) USE IN FEBRILE NEUTROPENIC EPISODES

MUSTAFA PEHLİVAN1, FATİH DEMİRKAN1, HAYRİ G. ÖZSAN1, UĞUR YILMAZ1, BÜLENT ÜNDAR1

Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, İZMİR

Keywords: g-csf use, febrile neutropenia
Febrile neutropenia (NP) is an important cause of mortality occurring commonly after myelosupressive treatment in cancer patients. In this study, during 92 febrile NP episodes, 55 G-CSF administered patients and 37 patients who were not administered G-CSF were compared in a non-random fashion. In both groups age and sex, hemotological malignancies/solid cancer and microbiologically documented infection distributions were found be similar. The effect of G-CSF, which is added to the empirical antibiotic therapy at the beginning of fever, on mortality, NP period, febrile episode period, hospital stay period because of antibiotic use and cost, was analyzed. In an analysis with stratification of two patient groups according to the severity of NP, G-CSF use has resulted in a slight diminution in the duration of NP in the patients with moderate NP (PNL 100-500 mm3) while causing a big difference in cost. Although no significant difference was found in the cost, an important decrease in the duration of NP (p<0.03) and mortality rate (p<0.03) was observed in G-CSF administered patients with profound NP (PNL (100 mm3). In conclusion, the use of G-CSF seems more reasonable and cost-effective in profound neutropenia.